Delzicol
Proctitis, Proctocolitis, Colitis, Ulcerative + 2 more
Treatment
1 FDA approval
0 Active Studies for Delzicol
Treatment for
Proctitis
What is Delzicol
Mesalazine
The Generic name of this drug
Treatment Summary
Mesalazine is an anti-inflammatory drug used to treat and keep ulcerative colitis in remission. It is related to aspirin and other non-steroidal anti-inflammatory drugs. In the past, mesalazine was difficult to keep stable, but now there are formulations such as Asacol and Pentasa that have been designed to make it more stable. Mesalazine has also been studied for its potential to reduce the risk of colorectal cancer in conditions like ulcerative colitis.
Rowasa
is the brand name
Delzicol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Rowasa
Mesalazine
1988
107
Approved as Treatment by the FDA
Mesalazine, otherwise called Rowasa, is approved by the FDA for 1 uses which include Crohn Disease .
Crohn Disease
Effectiveness
How Delzicol Affects Patients
Mesalazine is a component of sulphasalazine, and is the active part of the drug used to treat ulcerative colitis. It helps reduce inflammation by blocking the production of prostaglandins, leukotrienes and free radicals. Mesalazine is more effective when applied directly to the inflammation, rather than taken as a general medication. In experiments, it had similar effects to prednisolone and sulphasalazine in reducing inflammation in mice and guinea pigs.
How Delzicol works in the body
Mesalazine works to reduce inflammation in the colon. It does this by blocking the production of prostaglandins and leukotrienes, two molecules that are produced in large amounts when the body is suffering from inflammation. Mesalazine also works by blocking the activation of Nuclear Factor kappa B, which helps produce inflammatory cytokines, and by activating PPAR gamma receptors, which help reduce inflammation. Additionally, mesalazine has been shown to inhibit leukocyte chemotaxis, decrease cytokine and leukotriene production and scavenge for free radicals.
When to interrupt dosage
The dose of Delzicol is contingent upon the indicated condition. The amount of dosage fluctuates, contingent upon the technique of delivery outlined in the table below.
Condition
Dosage
Administration
Proctitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Enema, Enema - Rectal, Suspension - Rectal, Suspension, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, Delayed Release - Oral, Capsule - Oral, Capsule, Enema; Liquid - Rectal, Enema; Liquid, Kit - Rectal, Kit, Tablet, Delayed Release
Ulcerative Colitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Enema, Enema - Rectal, Suspension - Rectal, Suspension, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, Delayed Release - Oral, Capsule - Oral, Capsule, Enema; Liquid - Rectal, Enema; Liquid, Kit - Rectal, Kit, Tablet, Delayed Release
Proctocolitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Enema, Enema - Rectal, Suspension - Rectal, Suspension, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, Delayed Release - Oral, Capsule - Oral, Capsule, Enema; Liquid - Rectal, Enema; Liquid, Kit - Rectal, Kit, Tablet, Delayed Release
Crohn Disease
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Enema, Enema - Rectal, Suspension - Rectal, Suspension, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, Delayed Release - Oral, Capsule - Oral, Capsule, Enema; Liquid - Rectal, Enema; Liquid, Kit - Rectal, Kit, Tablet, Delayed Release
Colitis, Ulcerative
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Enema, Enema - Rectal, Suspension - Rectal, Suspension, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Tablet, extended release - Oral, Tablet, extended release, Tablet, Tablet - Oral, Tablet, Delayed Release - Oral, Capsule - Oral, Capsule, Enema; Liquid - Rectal, Enema; Liquid, Kit - Rectal, Kit, Tablet, Delayed Release
Warnings
Delzicol Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Mesalazine may interact with Pulse Frequency
There are 20 known major drug interactions with Delzicol.
Common Delzicol Drug Interactions
Drug Name
Risk Level
Description
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Mesalazine.
Methotrexate
Major
The serum concentration of Methotrexate can be increased when it is combined with Mesalazine.
Mifamurtide
Major
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Mesalazine.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Neomycin.
Omacetaxine mepesuccinate
Major
The risk or severity of bleeding can be increased when Mesalazine is combined with Omacetaxine mepesuccinate.
Delzicol Toxicity & Overdose Risk
Tests on rats found that taking up to 1.7 times the recommended dose of mesalazine for humans did not cause any increase in cancer, and it was not found to be mutagenic in several tests. However, overdose symptoms can include nausea, vomiting, fast or heavy breathing, ringing in the ears, confusion, and headache. Severe intoxication may also cause an imbalance of electrolytes and blood pH, and can affect other organs such as the kidneys and liver. There is no specific antidote to mesalazine overdose, but treatment may involve decontaminating the digestive tract and providing intravenous therapy to correct fluid and electrolyte
Delzicol Novel Uses: Which Conditions Have a Clinical Trial Featuring Delzicol?
Currently, 96 active studies are assessing the potential of Delzicol to provide relief from Ulcerative Colitis.
Condition
Clinical Trials
Trial Phases
Proctocolitis
0 Actively Recruiting
Proctitis
0 Actively Recruiting
Crohn Disease
0 Actively Recruiting
Colitis, Ulcerative
0 Actively Recruiting
Ulcerative Colitis
0 Actively Recruiting
Delzicol Reviews: What are patients saying about Delzicol?
5
Patient Review
9/18/2013
Delzicol for Ulcerative Colitis currently Without Symptoms
5
Patient Review
2/22/2014
Delzicol for Ulcerative Colitis currently Without Symptoms
4.3
Patient Review
9/6/2014
Delzicol for Ulcerative Colitis currently Without Symptoms
4.3
Patient Review
6/11/2014
Delzicol for Ulcerative Colitis currently Without Symptoms
4
Patient Review
6/18/2015
Delzicol for Crohn's Disease
4
Patient Review
7/30/2013
Delzicol for Ulcerative Colitis currently Without Symptoms
3.7
Patient Review
10/9/2015
Delzicol for Crohn's Disease
3.7
Patient Review
1/14/2016
Delzicol for Crohn's Disease
3.3
Patient Review
4/30/2015
Delzicol for Ulcerated Colon
3
Patient Review
10/22/2013
Delzicol for Crohn's Disease
3
Patient Review
7/27/2013
Delzicol for Ulcerated Colon
2.3
Patient Review
10/12/2013
Delzicol for Crohn's Disease
1
Patient Review
9/16/2013
Delzicol for Ulcerative Colitis currently Without Symptoms
1
Patient Review
9/26/2013
Delzicol for Ulcerative Colitis currently Without Symptoms
Patient Q&A Section about delzicol
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is DELZICOL the same as Asacol?
"These three medications work to lessen the inflammation caused by UC by containing the active ingredient mesalamine. By controlling the inflammation, the symptoms of UC can be more manageable."
Answered by AI
What is the difference between DELZICOL and mesalamine?
"DELZICOL is a medication used to treat mildly to moderately active ulcerative colitis. The active ingredient in DELZICOL is mesalamine, which is also known as 5-aminosalicylic acid or 5-ASA. Mesalamine is a common treatment for ulcerative colitis."
Answered by AI
What is DELZICOL used for?
"This medication is used to treat ulcerative colitis, a bowel disease that causes symptoms like diarrhea, rectal bleeding, and stomach pain. Mesalamine is an aminosalicylate, a class of drugs that work by decreasing swelling in the colon."
Answered by AI
How long does it take DELZICOL to work?
"This drug is called an aminosalicylate, which is also known as a 5-ASA. It helps to reduce the irritation and swelling (inflammation) in the lining of the intestines. If taken as prescribed, these drugs can work as quickly as 2 to 4 weeks."
Answered by AI